Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 1.00 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 1.00 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 1.00 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 1.00 |
| ▸ | DPP4 | P27487 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | SLC28A1 | O00337 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | SLC28A2 | O43868 | 1/20 | 1.00 |
| ▸ | GAPDH | P04406 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | PI4KA | P42356 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 1.00 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 1.00 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 1.00 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 1.00 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL14496806 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL10361572 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Vidarabine SCHEMBL110914 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL20399009 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL24538665 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2028876 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23804425 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL2403831 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL23420216 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 | |
| Adenosine SCHEMBL4403412 | 1.00 | ADORA3 (1.00) | ADORA3DPP4MEN1SLC28A1MAP3K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 341 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680230-A1 | METHOD OF TREATING TUBEROUS SCLEROSIS COMPLEX OR EPILEPSY AND COMPOSITION FOR USE THEREIN | Academia Sinica (TW) | 2026-01-21 | — | — | EP | claimed |
| WO-2025043082-A2 | COMPOSITIONS AND METHODS TO IMPROVE RNA PROPERTIES USING BASE, PHOSPHODIESTER LINKAGE, SUGAR BACKBONE, AND CAP MODIFICATIONS | THE BROAD INSTITUTE, INC. (US) | 2025-02-27 | — | — | WO | claimed |
| WO-2025036992-A1 | RNA CONJUGATES | CureVac SE (DE) | 2025-02-20 | — | — | WO | claimed |
| WO-2024196760-A1 | METHOD OF TREATING TUBEROUS SCLEROSIS COMPLEX OR EPILEPSY AND COMPOSITION FOR USE THEREIN | ACADEMIA SINICA (TW) | 2024-09-26 | — | — | WO | claimed |
| US-12071620-B2 | Polynucleotides containing a morpholino linker | MODERNATX, INC. (US) | 2024-08-27 | — | — | US | claimed |
| CN-117233278-A | Content determination method of standard decoction of rhizoma Panacis Japonici and construction method of characteristic map | 湖南春光九汇现代中药有限公司 | 2023-12-15 | — | — | CN | claimed |
| US-20230323344-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | ARES CAPITAL CORPORATION, AS AGENT | 2023-10-12 | — | — | US | claimed |
| EP-4101930-A1 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | ModernaTX, Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| US-11434486-B2 | Polynucleotides containing a morpholino linker | MODERNATX, INC. (US) | 2022-09-06 | — | — | US | claimed |
| US-20220251577-A1 | ENDONUCLEASE-RESISTANT MESSENGER RNA AND USES THEREOF | MODERNATX, INC. | 2022-08-11 | — | — | US | claimed |
| EP-4018200-A1 | METHODS, KITS AND COMPOSITIONS FOR DIAGNOSING AND TREATING RENAL DISEASE | Hill's Pet Nutrition, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| EP-3987027-A1 | ENDONUCLEASE-RESISTANT MESSENGER RNA AND USES THEREOF | ModernaTX, Inc. (US) | 2022-04-27 | — | — | EP | claimed |
| WO-2026102302-A1 | POLYNUCLEOTIDES CONTAINING A MODIFIED 3'-REGION | MODERNATX, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4573215-B1 | CELL-FREE METHOD OF PRODUCING SYNTHETIC CIRCULAR NUCLEIC ACID | ALDEVRON L L C (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12600965-B2 | Modified double stranded oligonucleotide | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| WO-2005037214-A2 | MACROCYCLIC CARBOXYLIC ACIDS AND ACYLSULFONAMIDES AS INHIBITORS OF HCV REPLICATION | INTERMUNE, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-0788506-A2 | L-RIBOFURANOSYL NUCLEOSIDES | GENENCOR INTERNATIONAL, INC. (US) | 1997-08-13 | — | — | EP | disclosed |
| US-5559101-A | ANTITUMOR, ANTICARCINOGENIC, HIV | GENENCOR INTERNATIONAL, INC. (US) | 1996-09-24 | — | — | US | disclosed |
| WO-1996013512-A2 | L-RIBOFURANOSYL NUCLEOSIDES | GENENCOR INTERNATIONAL, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12600965-B2 | Modified double stranded oligonucleotide | NSUN2, EIF2AK2, ADAR | ADORA3 745/4885ADORA2A 277/4885ADORA2B 253/4885 |
| US-20220251577-A1 | ENDONUCLEASE-RESISTANT MESSENGER RNA AND USES THEREOF | RNASE1, RNASEH1, NSUN3 | ADORA3 3427/4885ADORA2A 2894/4885ADORA2B 2837/4885 |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | AGT, AGTR2, AGTR1 | ADORA3 1016/4885ADORA2A 631/4885ADORA2B 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.